Managing Director & Senior Partner
André Kronimus is Boston Consulting Group’s global topic leader for corporate finance and strategy in health care (biopharma and medtech) and chemicals. He is a member of the firm’s global Health Care and Corporate Finance and Strategy practice leadership teams and coleads BCG's Corporate Finance Task Force in Europe. He is also a core member of the Industrial Goods practice, with a particular focus on the chemical and agrochemical industry.
Since joining BCG in 2003, André has worked extensively in mergers and acquisitions in the US, Europe, and Asia, on both the buy and sell sides.
He has also worked with numerous clients on a wide range of corporate development topics, including corporate and portfolio strategy, growth strategy, and industry landscaping, plus finance organization and processes, primarily in the biopharma, medtech, and chemical sectors. André frequently advises private-equity funds on due diligence and portfolios.
Before joining BCG, André worked as a research and teaching assistant in finance at the WHU Otto Beisheim School of Management.
Through carve-outs, companies can create value, streamline portfolios, and reduce complexity. But the ultimate success of a deal hinges on focused, proactive execution.
More companies are forging strategic alliances as they seek competitive advantage. Here’s what they must do to build and manage them successfully.
Teams often struggle to execute external licensing agreements and M&A transactions that can supplement internal innovation and revenue. Six factors can enhance performance.
The new US tax law is likely to reshape corporate portfolios, provided buyers and sellers can overcome the new big uncertainty that the regime introduces—its own duration.
Although small in scale relative to the acquiring company, midsize acquisitions are becoming important to creating value in the biopharmaceutical industry.
The global health-care industry is at an inflection point, and services companies must take decisive steps if they are to continue creating value for their investors.
Having outperformed the overall capital market in recent years, medical-technology companies now face sizable shifts in the health care environment that will dictate fundamental changes in their operating model.
The health care industry is changing, and biopharmaceutical companies need to take decisive action to ensure that their recent strong value-creation performance remains sustainable.
M&A is increasingly necessary, but extracting value is more difficult than it was in the past. What should pharmaceutical companies do?